Is LENZ Therapeutics, Inc. (LENZ) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 57.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 57.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.6% / 33% | 97.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 57.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.6% / 33% | 97.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 97.8% | |
| Operating Margin | -2422.1% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -33.6% | |
| Return on Assets (ROA) | -21.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$59M |
| Free Cash Flow | -$60M |
| Total Debt | $1M |
| Debt-to-Equity | 0.3 |
| Current Ratio | 14.2 |
| Total Assets | $215M |
Price & Trading
| Last Close | $8.94 |
| 50-Day MA | $13.86 |
| 200-Day MA | $27.22 |
| Avg Volume | 954K |
| Beta | 1.8 |
|
52-Week Range
$8.39
| |
About LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is LENZ Therapeutics, Inc. (LENZ) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), LENZ Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is LENZ Therapeutics, Inc.'s debt ratio?
LENZ Therapeutics, Inc.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.6%.
What are LENZ Therapeutics, Inc.'s key financial metrics?
LENZ Therapeutics, Inc. has a market capitalization of $263M. Return on equity stands at -33.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.